On Tuesday, Plus Therapeutics Inc (NASDAQ: PSTV) was 8.74% up from the session before settling in for the closing price of $0.64. A 52-week range for PSTV has been $0.24 – $2.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 383.24% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 57.69%. With a float of $16.57 million, this company’s outstanding shares have now reached $17.00 million.
In an organization with 21 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -0.1%, operating margin of -497.12%, and the pretax margin is -439.04%.
Plus Therapeutics Inc (PSTV) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Plus Therapeutics Inc stocks. The insider ownership of Plus Therapeutics Inc is 2.55%, while institutional ownership is 8.04%. The most recent insider transaction that took place on May 15 ’25, was worth 20,276. Before that another transaction happened on Sep 13 ’24, when Company’s Director bought 4,000 for $1.50, making the entire transaction worth $5,996. This insider now owns 15,188 shares in total.
Plus Therapeutics Inc (PSTV) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 57.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 49.89% during the next five years compared to 46.51% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
You can see what Plus Therapeutics Inc (PSTV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.31. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.06, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.76 in one year’s time.
Technical Analysis of Plus Therapeutics Inc (PSTV)
Let’s dig in a bit further. During the last 5-days, its volume was 1.14 million. That was inferior than the volume of 11.78 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 62.52%. Additionally, its Average True Range was 0.14.
During the past 100 days, Plus Therapeutics Inc’s (PSTV) raw stochastic average was set at 22.13%, which indicates a significant decrease from 43.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 153.14% in the past 14 days, which was lower than the 344.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8593, while its 200-day Moving Average is $1.2074. However, in the short run, Plus Therapeutics Inc’s stock first resistance to watch stands at $0.7487. Second resistance stands at $0.7993. The third major resistance level sits at $0.8687. If the price goes on to break the first support level at $0.6287, it is likely to go to the next support level at $0.5593. The third support level lies at $0.5087 if the price breaches the second support level.
Plus Therapeutics Inc (NASDAQ: PSTV) Key Stats
There are 17,000K outstanding shares of the company, which has a market capitalization of 11.87 million. As of now, sales total 5,820 K while income totals -12,980 K. Its latest quarter income was 1,410 K while its last quarter net income were -3,900 K.
